Rituximab-ILD may be caused by the fact that it binds to and kills B cells, resulting in the release of TNF-α IFN-α IL-6 IL-8 and other cytokines by T lymphocytes (Lands, 2010), it may also be caused by a type III hypersensitivity reaction triggered due to its immunogenicity (Lioté et al., 2010). Here, IL6 is linked to interstitial lung disease.